Future COVID-19 vaccine possibly priced under €10

Future COVID-19 vaccine possibly priced under €10

Sanofi is considering releasing an active pharmaceutical ingredients company

A few days after they announced that their joint vaccine would undergo human clinical trials, Sanofi and GSK started the week with additional news regarding the vaccine.

Oliver Bogillot, Sanofi’s French CEO, announced that the vaccine's price would be €10 or less. Despite the announcement, he iterated the fact that the final price hadn't been set yet.

Besides the price, the Sanofi plans to list its active pharmaceutical ingredients (API) company publicly. The initial public offering is scheduled to happen in the following months, and the new business could be valued at up to €2billion.

It is the embodiment of a plan touted in February, through which Sanofi will create a standalone company by reuniting under the same roof its commercial and development activities and the power of its six European production sites.

According to Sanofi, the move would balance the industry's reliance on Asia for ingredients, which lately has been disrupted by the pandemic. The drugmaker said that it is taking into consideration a 2022 Euronext Paris listing. If it does it, the new API would be the second-largest in the world after the Swiss Lonza.

Following the news, Sanofi stock price gained 2%.

If you are interested in trading companies that are in the race of developing a COVID-19 vaccine, check-out our COVID Blend!

Sources: marketwatch.com, finance.yahoo.com

The information presented herein is prepared by CAPEX.com and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.

Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.